# Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

> **NCT04060394** · PHASE1,PHASE2 · COMPLETED · sponsor: **Laekna Limited** · enrollment: 49 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Phase I and Phase II: LAE001/prednisone + afuresertib

## Key facts

- **NCT ID:** NCT04060394
- **Lead sponsor:** Laekna Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-13
- **Primary completion:** 2023-12-27
- **Final completion:** 2024-03-30
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2024-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04060394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04060394, "Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04060394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*